Human Interferon-Induced Protein Blocks Zika Virus Infection
|
By LabMedica International staff writers Posted on 15 Jun 2016 |

Image: IFITM3 blocks Zika virus infection. When human cells are exposed to Zika virus they are overwhelming infected, as seen by the large number of green cells (left panel). When IFITM3 levels were boosted in these cells, the same amount of virus was prevented from replicating (right panel) (Photo courtesy of Brass Lab, University of Massachusetts Medical School).
A team of molecular virologists has shown that the human protein IFITM3 (interferon-induced protein 3) inhibits Zika virus infection early in the viral life cycle and can prevent Zika-virus-induced cell death.
The IFITM family of restriction factors has been found to inhibit the replication of a broad range of viruses, including the closely related flaviruses West Nile virus and dengue virus.
Investigators at the University of Massachusetts Medical School (Worcester, USA) used tools and assays that had been developed for studying IFITM3 in dengue and influenza virus infections to evaluate the effect of this factor on Zika virus.
They reported in the June 3, 2016, online edition of the journal Cell Reports that IFITM3 and the closely related IFITM1 inhibited Zika virus infection early in the viral life cycle. Moreover, IFITM3 was shown to prevent Zika-virus-induced cell death.
"We simply adapted the technology we had developed over the last four years working with dengue, influenza, and other viruses to begin work on Zika virus," said senior author Dr. Abraham Brass, assistant professor of microbiology and physiological systems at the University of Massachusetts Medical School.
"This work represents the first look at how our cells defend themselves against Zika virus' attack," said Dr. Brass. "Our results show that Zika virus has a weakness that we could potentially exploit to prevent or stop infection. A lot of data by us and others in the field has shown that IFITM3 has a big impact on blocking many emerging viruses such as dengue, Zika, and Ebola. Given our recent results with Zika virus, it is now even more important that we work to find out how IFITM3 is blocking these viruses, and use that knowledge to prevent and treat infections."
Related Links:
University of Massachusetts Medical School
The IFITM family of restriction factors has been found to inhibit the replication of a broad range of viruses, including the closely related flaviruses West Nile virus and dengue virus.
Investigators at the University of Massachusetts Medical School (Worcester, USA) used tools and assays that had been developed for studying IFITM3 in dengue and influenza virus infections to evaluate the effect of this factor on Zika virus.
They reported in the June 3, 2016, online edition of the journal Cell Reports that IFITM3 and the closely related IFITM1 inhibited Zika virus infection early in the viral life cycle. Moreover, IFITM3 was shown to prevent Zika-virus-induced cell death.
"We simply adapted the technology we had developed over the last four years working with dengue, influenza, and other viruses to begin work on Zika virus," said senior author Dr. Abraham Brass, assistant professor of microbiology and physiological systems at the University of Massachusetts Medical School.
"This work represents the first look at how our cells defend themselves against Zika virus' attack," said Dr. Brass. "Our results show that Zika virus has a weakness that we could potentially exploit to prevent or stop infection. A lot of data by us and others in the field has shown that IFITM3 has a big impact on blocking many emerging viruses such as dengue, Zika, and Ebola. Given our recent results with Zika virus, it is now even more important that we work to find out how IFITM3 is blocking these viruses, and use that knowledge to prevent and treat infections."
Related Links:
University of Massachusetts Medical School
Latest BioResearch News
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
- Common White Blood Cells Produce Schizophrenia-Linked Protein
- Nanopore Method Captures RNA Folding at Single-Molecule Resolution
- Tumor Microenvironment Marker Linked to Worse Survival in Solid Tumors
- Hidden Immune Gene Defect May Explain Kaposi Sarcoma Susceptibility
- Genetic Markers May Help Predict Amputation Risk in Peripheral Artery Disease
- Gene Signature Shows Promise for Depression Biomarker Testing
- AI-Driven Tumor Profiling Initiative Targets Precision Therapy Development
- Researchers Map Protein and Glycosylation Across 15 Human Body Fluids
- Telomere Length Abnormalities Linked to Lymphoma Development
- Biomarker Signals Chemotherapy Resistance in Relapsed Small Cell Lung Cancer
- Inflammatory Gene Signature Links Metabolic Disease to Pancreatic Cancer Recurrence
Channels
Clinical Chemistry
view channel
Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more
Plasma Vitamin C Levels Associated with Brain Structure and Connectivity in Aging
Previous studies have linked vitamin C–rich diets with lower risk of cognitive impairment in older adults. However, few investigations have directly examined blood plasma vitamin C in relation to brain... Read more
Mass Spectrometry Detects Tumor Metabolites for Cancer Monitoring
Cancer’s altered metabolism complicates how clinicians detect and monitor tumors, because nutrient use can shift with context and time. Measuring small-molecule metabolites that distinguish malignant from... Read more
Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures
Many patients with type 2 diabetes and chronic kidney disease continue to experience progressive renal decline, yet conventional markers such as albuminuria and estimated glomerular filtration rate (eGFR)... Read moreMolecular Diagnostics
view channel
Ultrasensitive HPV Blood Test Predicts Early Recurrence in Head and Neck Cancer
Human papillomavirus (HPV)-associated head and neck cancers are frequently treated with surgery, but some patients experience recurrence due to residual microscopic disease. Postoperative decisions about... Read more
New Library Normalization and Amplification Tools Support Oncology Sequencing
High-throughput next-generation sequencing (NGS) laboratories continue to grapple with uneven library pooling and amplification artifacts that can degrade variant calling accuracy and increase reruns.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
Congenital TORCH infections can be asymptomatic during pregnancy yet cause stillbirth, birth defects, and lifelong disability in infants. Many regions still lack robust surveillance to guide testing and... Read more
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read morePathology
view channel
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
AI Tool Speeds Brain Tumor Classification from Routine Histology Slides
Accurate classification of brain and spinal cord tumors increasingly depends on molecular profiling alongside histology, but access to such testing remains limited and results can take about two weeks.... Read more
IHC Companion Diagnostic Standardizes Mismatch Repair Testing for Cancer Immunotherapy
Deficient DNA mismatch repair is an established predictive biomarker for response to immune checkpoint inhibitors, yet access to standardized assessment has varied across tumor types. Cancer remains the... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Open-Source Consortium Aims to Standardize Digital Pathology Workflows
Digital pathology is expanding rapidly as laboratories adopt whole-slide imaging and computational tools to meet growing diagnostic and biomarker-testing demand. However, fragmented software infrastructure... Read more








